$2.55T
Total marketcap
$182.75B
Total volume
BTC 50.08%     ETH 15.86%
Dominance

Vertex Pharmaceuticals Incorporated VRTX Stock

411.38 USD {{ price }} 0.905100% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
106.26B USD
LOW - HIGH [24H]
409.25 - 415.5 USD
VOLUME [24H]
926.25K USD
{{ volume }}
P/E Ratio
29.59
Earnings per share
13.9 USD

Vertex Pharmaceuticals Incorporated Price Chart

Vertex Pharmaceuticals Incorporated VRTX Financial and Trading Overview

Vertex Pharmaceuticals Incorporated stock price 411.38 USD
Previous Close 400.63 USD
Open 403.59 USD
Bid 405 USD x 800
Ask 406.97 USD x 800
Day's Range 402.35 - 406.91 USD
52 Week Range 282.21 - 413 USD
Volume 804.29K USD
Avg. Volume 1.41M USD
Market Cap 104.43B USD
Beta (5Y Monthly) 0.417
PE Ratio (TTM) 30.40135
EPS (TTM) 13.9 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 411.04 USD

VRTX Valuation Measures

Enterprise Value 93.24B USD
Trailing P/E 30.40135
Forward P/E 24.695309
PEG Ratio (5 yr expected) 2.35
Price/Sales (ttm) 10.816643
Price/Book (mrq) 6.3274837
Enterprise Value/Revenue 9.658
Enterprise Value/EBITDA 20.403

Trading Information

Vertex Pharmaceuticals Incorporated Stock Price History

Beta (5Y Monthly) 0.417
52-Week Change N/A
S&P500 52-Week Change N/A
52 Week High 413 USD
52 Week Low 282.21 USD
50-Day Moving Average 368.61 USD
200-Day Moving Average 347.07 USD

VRTX Share Statistics

Avg. Volume (3 month) 1.41M USD
Avg. Daily Volume (10-Days) 2.16M USD
Shares Outstanding 257.68M
Float 257M
Short Ratio 1.82
% Held by Insiders 0.10%
% Held by Institutions 96.01%
Shares Short 2.69M
Short % of Float 1.04%
Short % of Shares Outstanding 1.04%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 2:1

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) September 30, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 35.93%
Operating Margin (ttm) 43.92%
Gross Margin 61.60%
EBITDA Margin 47.33%

Management Effectiveness

Return on Assets (ttm) 14.34%
Return on Equity (ttm) 23.48%

Income Statement

Revenue (ttm) 9.65B USD
Revenue Per Share (ttm) 37.49 USD
Quarterly Revenue Growth (yoy) 6.40%
Gross Profit (ttm) 5.32B USD
EBITDA 4.57B USD
Net Income Avi to Common (ttm) 3.47B USD
Diluted EPS (ttm) 13.33
Quarterly Earnings Growth (yoy) 11.30%

Balance Sheet

Total Cash (mrq) 11.93B USD
Total Cash Per Share (mrq) 46.29 USD
Total Debt (mrq) 744.7M USD
Total Debt/Equity (mrq) 4.51 USD
Current Ratio (mrq) 4.083
Book Value Per Share (mrq) 64.046

Cash Flow Statement

Operating Cash Flow (ttm) 4.38B USD
Levered Free Cash Flow (ttm) 3.92B USD

Profile of Vertex Pharmaceuticals Incorporated

Country United States
State MA
City Boston
Address 50 Northern Avenue
ZIP 02210
Phone 617 341 6100
Website https://www.vrtx.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 4800

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Q&A For Vertex Pharmaceuticals Incorporated Stock

What is a current VRTX stock price?

Vertex Pharmaceuticals Incorporated VRTX stock price today per share is 411.38 USD.

How to purchase Vertex Pharmaceuticals Incorporated stock?

You can buy VRTX shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Vertex Pharmaceuticals Incorporated?

The stock symbol or ticker of Vertex Pharmaceuticals Incorporated is VRTX.

Which industry does the Vertex Pharmaceuticals Incorporated company belong to?

The Vertex Pharmaceuticals Incorporated industry is Biotechnology.

How many shares does Vertex Pharmaceuticals Incorporated have in circulation?

The max supply of Vertex Pharmaceuticals Incorporated shares is 258.31M.

What is Vertex Pharmaceuticals Incorporated Price to Earnings Ratio (PE Ratio)?

Vertex Pharmaceuticals Incorporated PE Ratio is 29.59568400 now.

What was Vertex Pharmaceuticals Incorporated earnings per share over the trailing 12 months (TTM)?

Vertex Pharmaceuticals Incorporated EPS is 13.9 USD over the trailing 12 months.

Which sector does the Vertex Pharmaceuticals Incorporated company belong to?

The Vertex Pharmaceuticals Incorporated sector is Healthcare.

Vertex Pharmaceuticals Incorporated VRTX included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
S&P 500 (Yahoo.com) GSPC 5149.42 USD
+0.63
2.4B USD 5145.47 USD 5175.6 USD 2.4B USD
S&P 500 INDEX SPX 5149.42 USD
+0.63
2.39B USD 2.39B USD
US100 NDX 17985.01 USD
+0.99
934.12M USD 17973.09 USD 18124.32 USD 934.12M USD
Dow Jones U.S. Biotechnology In DJUSBT 2844.59 USD
+0.08
79.29M USD 2839.63 USD 2860.51 USD 79.29M USD
NASDAQ Biotechnology Total Retu XNBI 4654.3 USD
-0.65
4652.69 USD 4696.7 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD
NASDAQ-100 PM Settlement Value XQC 16331.98 USD
+1.13
16331.98 USD 16331.98 USD
NASDAQ 100 After Hours Indicato QIV 17954.86 USD
+0.82
17937.48 USD 17997.94 USD
Nasdaq US Smart Pharmaceuticals NQSSPH 1454.2 USD
-0.47
1453.71 USD 1464.83 USD
NASDAQ Global Select Market Com NQGS 7837.41 USD
+0.85
7832.7 USD 7908.95 USD
NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD 2100.38 AUD 1390.15 USD
<0.01
2100.38 AUD 1390.15 USD 2100.38 AUD 1390.15 USD
Nasdaq-100 ESG Net Notional Tot NDXESG24 1471.66 EUR 1608.72 USD
+0.91
1471.53 EUR 1608.58 USD 1484.15 EUR 1622.38 USD
NASDAQ 100 Notional Net Total R XNDXNNR 20704.93 USD
+0.99
20691.19 USD 20865.32 USD